About US
Contact us
-
AC Immune and Essex to develop biological treatment for neurodegenerative diseasesAC Immune and Essex Bio-Technology have signed a research collaboration agreement to conduct a pre-clinical study and clinical codevelopment of a novel biological therapeutic to treat neurodegenerativ2017/6/5
-
Cancer Research UK funded scientists to test Zika virus on brain tumoursScientists funded by Cancer Research UK will investigate the effectiveness of the Zika virus in destroying brain tumour cells, which could lead to new treatments for cancer. Under the initiative, Dr2017/6/5
-
Sobi receives SFDA approval for Orfadin capsulesSpecialist healthcare company Swedish Orphan Biovitrum (Sobi) has received approval from the Saudi Food and Drug Administration (SFDA) for Orfadin (nitisinone) capsules in strengths of 2mg, 5mg, 10mg2017/6/2
-
X-Chem and Vertex form multi-target genetic disease collaborationUS-based firms X-Chem and Vertex Pharmaceuticals have signed a collaboration agreement to discover new drug leads against targets involved in multiple speciality diseases. Under the agreement, X-Chem2017/6/2
-
Bayer receives FDA priority review for copanlisib to treat follicular lymphomaGerman drug manufacturer Bayer has received priority review designation for the new drug application (NDA) for copanlisib from the US Food and Drug Administration (FDA). The experimental drug is indi2017/6/1
-
Eli Lilly Scores Phase III Migraine Success with GalcanezumabOn May 12, 2017, Eli Lilly announced the successful Phase III results for its calcitonin gene-related peptide (CGRP) monoclonal antibody, galcanezumab, for the prophylactic treatment of episodic and c2017/6/1
-
EU nations urge funding to research new drugs and vaccines for tuberculosisLeaders representing the French and Netherlands governmentshave urged for funding to develop new treatment and prevention tools against drug-resistant tuberculosis (TB) at a meeting held in Brussels.2017/5/31
-
US FDA issues CRL to Hikma’s generic version of GSK’s Advair DiskusHikma Pharmaceuticals has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of its generic version of GlaxoSmithK2017/5/31
-
Good Distribution Practices for Pharmaceutical ExcipientsIPEC Europe is pleased to announce that this important webinar will be held on 22 June 2017, at 14:30 CEST. The IPEC Federation very recently revisedits Good Distribution Practices for Pharmaceutic2017/5/26
-
EU officials question 'unjustified' cancer drug pricing from AspenUpon receiving information thatAspen Pharmacare has taken steep price increases on lifesaving cancer meds in Europe and threatened to pull its products in order to get the hikes through, EUantitrust r2017/5/26